Categories: News

Cell Impact to deliver tool to leading automotive manufacturer

KARLSKOGA, Sweden, Dec. 9, 2025 /PRNewswire/ — Cell Impact has signed an agreement with a leading Asian automotive manufacturer for the production and delivery of a forming tool used in the manufacturing of flow plates. The order is valued at SEK 1.5 million, with delivery expected during Q1 2026.

- Advertisement -

 

- Advertisement -

The automotive manufacturer and Cell Impact have collaborated for several years through multiple customer projects, and this latest agreement is the result of previous successful initiatives.

- Advertisement -

“Each successful project has brought us one step closer to continuous production. The tool in question will be used by the customer to manufacture complete flow plates for testing and validation of pattern design and production quality,” says Daniel Vallin, CEO of Cell Impact.

- Advertisement -

The order will have a limited impact on Cell Impact’s earnings for the current year but is strategically important as it moves the collaboration closer to full-scale production at the customer.

- Advertisement -

About Cell Impact
Cell Impact AB (publ) is a global supplier of advanced flow plates to fuel cell and electrolyzer manufacturers. The company has developed and patented a unique method for high velocity forming, Cell Impact Forming™ which is significantly more scalable and cost-efficient compared to conventional forming methods. Cell Impact Forming is an environmentally friendly forming technology that consumes no water and very little electrical power.
The Cell Impact share is listed on Nasdaq First North Growth Market and FNCA Sweden AB is the company’s Certified Advisor (CA).

- Advertisement -

Photo – https://mma.prnewswire.com/media/2841681/Cell_Impact_AB_Photo.jpg
Logo – https://mma.prnewswire.com/media/2816030/5663076/Cell_Impact_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/cell-impact-to-deliver-tool-to-leading-automotive-manufacturer-302636718.html

- Advertisement -

Recent Posts

FemiCore (Official Website & Authenticity Notice 2026) Counterfeit Risks and What Consumers Should Know

New York City, NY, June 13, 2026 (GLOBE NEWSWIRE) -- The women's health supplement market…

16 hours ago

Hitch Open Ping-Pong Embodied (HOPE) AI Challenge Joins the 2026 World Humanoid Robot Games, Seeding Advanced Physical AI Against Human Performance

BEIJING, June 13, 2026 (GLOBE NEWSWIRE) -- The 2026 Hitch Open Ping-Pong Embodied AI Challenge…

16 hours ago

Crypto News Today: AlphaPepe Unveils AlphaSwap Early Access as Bitcoin Price Prediction Eyes $250,000

MONACO, June 12, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning toward AlphaPepe after…

16 hours ago

Hexaware Expands Presence in Gujarat with New Delivery Center at GIFT City

MUMBAI, India, LONDON and ISELIN, N.J., June 13, 2026 /PRNewswire/ -- Hexaware Technologies [NSE: HEXT], a…

18 hours ago

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI…

19 hours ago

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

June 13, 2026 07:30 ET  | Source: Intellia Therapeutics, Inc. Data from HAELO Phase 3…

19 hours ago